Granules India, a company in the Pharmaceuticals industry, reported revenue of ₹1,560 crore and net profit of ₹182 crore for the September 2026 quarter.
Granules India (NSE: GRANULES) closed at ₹822.65 on 20 Nov 2026, up 49.4% over the past year. Its market capitalisation is ₹22,440 crore and it trades at 32.0 times earnings.
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.